| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$49,662,826 |
|
|
|
Indirect Value
|
$10,165,498 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$59,828,324 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 55.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
SVP, PreclinDevel & Biomol Sci |
• – – |
2003-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,977 |
17,441 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2005-11-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
500 |
4,871 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2010-12-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-11-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
250 |
18,584 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-05-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
16,405 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2016-02-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,500 |
40,470 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2016-11-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
7,876 |
23,950 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-05-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,300 |
21,150 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,625 |
11,380 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
750 |
20,979 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,688 |
24,715 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-02-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
435 |
24,280 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-11-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,605 |
28,809 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-11-29 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,605 |
4,605 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,926 |
53,883 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-02-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
335 |
52,795 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-11-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
330 |
52,465 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,101 |
53,100 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-11-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
400 |
52,700 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
853 |
52,744 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,020 |
50,999 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-03 |
4 |
OE |
$7.41 |
$296,400 |
D/D |
40,000 |
27,127 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-13 |
4 |
OE |
$8.50 |
$566,661 |
D/D |
66,666 |
92,177 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2007-04-20 |
4 |
OE |
$8.77 |
$219,250 |
D/D |
25,000 |
29,297 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2008-09-29 |
4 |
OE |
$8.77 |
$219,250 |
D/D |
25,000 |
25,350 |
0 |
- |
|
140 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
